Precigen Gross Margin 2012-2021 | PGEN

Current and historical gross margin for Precigen (PGEN) over the last 10 years. The current gross profit margin for Precigen as of September 30, 2021 is %.
Precigen Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $0.10B $0.04B 43.00%
2021-06-30 $0.10B $0.05B 46.08%
2021-03-31 $0.10B $0.04B 44.90%
2020-12-31 $0.10B $0.05B 46.60%
2020-09-30 $0.10B $0.04B 43.56%
2020-06-30 $0.10B $0.04B 40.00%
2020-03-31 $0.10B $0.04B 38.78%
2019-12-31 $0.09B $0.03B 32.97%
2019-09-30 $0.11B $0.05B 44.44%
2019-06-30 $0.12B $0.06B 50.00%
2019-03-31 $0.13B $0.07B 53.73%
2018-12-31 $0.15B $0.09B 58.28%
2018-09-30 $0.18B $0.12B 65.38%
2018-06-30 $0.20B $0.13B 67.86%
2018-03-31 $0.21B $0.14B 70.24%
2017-12-31 $0.22B $0.16B 72.15%
2017-09-30 $0.20B $0.14B 69.50%
2017-06-30 $0.20B $0.14B 69.95%
2017-03-31 $0.20B $0.14B 68.81%
2016-12-31 $0.19B $0.13B 67.54%
2016-09-30 $0.19B $0.12B 66.67%
2016-06-30 $0.19B $0.13B 66.84%
2016-03-31 $0.18B $0.12B 65.38%
2015-12-31 $0.17B $0.11B 64.16%
2015-09-30 $0.16B $0.10B 62.58%
2015-06-30 $0.13B $0.08B 61.07%
2015-03-31 $0.10B $0.07B 66.33%
2014-12-31 $0.07B $0.05B 73.61%
2014-09-30 $0.05B $0.04B 87.50%
2014-06-30 $0.03B $0.03B 100.00%
2014-03-31 $0.03B $0.03B 100.00%
2013-12-31 $0.02B $0.02B 100.00%
2013-06-30 $0.01B $0.01B 100.00%
2013-03-31 $0.01B $0.01B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.798B $0.103B
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09